A novel topical formulation of a BRAF inhibitor significantly reduced acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer, a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback